The expression and localisation of β-nerve growth factor (β-NGF) in benign and malignant human prostate tissue: Relationship to neuroendocrine differentiation

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1990-1996

  Paul, A B ^a,b   Grant, E S ^a   Habib, F K ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Human benign hyperplastic tissue; Nerve growth factor; Neuroendocrine cells; Prostate cancer; Sympathetic nerve

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NERVE GROWTH FACTOR BETA SUBUNIT;

ADOLESCENT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030443759     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.665     Document Type: Article

References (37)

1. ALLEN FJ, VAN VELDEN DJJ AND HEYNS CF. (1995). Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Brit. J. Urol., 75, 751-754.
2. APRIKIAN AG, CORDON-CARDO C, FAIR WR, ZHANG Z-F, BAZINET M, HAMDY SF AND REUTER VE. (1994). Neuroendocrine differentiation in metastatic prostatic carcinoma. J. Urol., 151, 914-919.
3. BANCROFT JD AND COOK HC. (1994). Immunocytochemistry. In Manual of Histological Techniques and their Diagnostic Applications, Bancroft JD and Cook HC. (eds) pp. 263-288. Churchill Livingstone: Edinburgh.
4. BERNER A, NESLAND JM, WAEHRE H, SILDE J AND FOSSA SD. (1993). Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. Br. J. Cancer, 68, 380-384.
5. BONKHOFF H, STEIN U AND REMBERGER K. (1993). Androgen receptor status in endocrine paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows. Arch. A. Pathol. Anat., 423, 291-294.
6. BORSANI G, PIZZUTI A, RUGARLI EI, FALINI A, SILANI V, SIDOLI A, SCARLATO G AND BARELLE FE. (1990). cDNA sequence of human beta-NGF. Nucleic Acids Res., 18, 4020.
7. BRADFORD M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72, 248-254.
8. BRADSHAW RA. (1978). Nerve growth factor. Annu. Rev. Biochem., 47, 191-216.
9. BUXSER SE, PUMA P AND JOHNSON GL. (1984). Properties of the nerve growth factor receptor. Relationship between receptor structure and function. J. Biol. Chem., 260, 1917-1926.
10. CHOMCZYNSKI P AND SACCHI N. (1987). Single-step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction. Anal. Biochem., 162, 156-159.
11. COHEN RJ, GLEZERSON G AND HAFFEJEE Z. (1991). Neuroendocrine cells a new prognostic parameter in prostate cancer. Br. J. Urol., 68, 258-262.
12. DESCHRYVER-KECSKEMETI K, BALOGH K AND NEET KE. (1987). Nerve-growth factor and the concept of neural epithelial interactions. Arch. Path. Lab. Med., 111, 833-835.
13. DI SANT-AGNESE PA. (1995). Neuroendocrine differentiation in prostatic carcinoma: recent findings and new concepts. Cancer, 75 (suppl). 1850-1859.
14. DI SANT-AGNESE PA AND JENSEN KLDeM. (1987). Neuroendocrine differentiation in prostatic carcinoma. Hum. Pathol.. 18, 849-856.
15. DJAKIEW D, DELSITE R, PFLUG B, WRATHALL J, LYNCH JH AND ONODA M. (1991). Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res., 51, 3304-3310.
16. GRAHAM CW, LYNCH JH AND DJAKIEW D. (1992). Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J. Urol., 147, 1444-1447.
17. GUNDERSEN RW AND BARRETT JN. (1980). Characterization of the turning response of dorsal-root neurites toward nerve growth factor. J. Cell Biol., 87, 546-554.
18. HARPER GP AND THOENEN H. (1980). The distribution of nerve growth factor in the male sex organs of mammals. J. Neurochem., 34, 893-903.
19. IWAMURA M, GERSHAGEN S, WU G, COCKETT AT, DI SANT-AGNESE PA AND ABRAHAMSSON PA. (1994). Distribution and androgen receptor status of neuroendocrine cells in the prostate. J. Urol., 151 (suppl.), 296A.
20. JENTSCH S. (1992). The ubiquitin-conjugation system. Annu. Rev. Genet., 26, 179-207.
21. KOGNER P, BARBANY G, DOMINICI C, CASTELLO MA, RASCHELLA G AND PERSSON H. (1993). Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res., 53, 2044-2050.
22. KORSCHING S AND THOENEN H. (1983). Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: correlation with density of sympathetic innervation. Proc. Natl Acad. Sci. USA. 80, 3513-3516.
23. LAEMMLI U. (1970). Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature, 227, 680-685.
24. LEPOR H AND SHAPIRO E. (1990). This month in investigative urology: alpha adrenergic innervation of the prostate: insights into pharmacotherapy of BPH. J. Urol., 143, 590-591.
25. MACGROGAN D, DESPRÉS G, ROMAND R AND DICOU H. (1990). Expression of the β-nerve growth factor gene in male sex organs of the mouse, rat, and guinea pig. J. Neurosci. Res., 28, 567-573
26. MACGROGAN D, SAINT-ANDRE JP AND DICOU E. (1992). Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J. Neurochem., 59, 1381-1391.
27. NAHER-NOE M, GNAHN H, GRUNDLER A, KLINGELHOFER J, WEINDL A AND CONRAD B. (1993). Determination of nerve growth factor concentrations in human samples by two-site immunoenzymometric assay and bioassay. Eur. J. Clin. Chem. Clin. Biochem., 31, 375-380.
28. NIKOLICS K. (1993). Identification of neurotrophic factors by molecular biological techniques. In Neurotrophic Factors, Boulton AA, Baker GB and Hefti F. (eds) pp. 25-55. Humana: New Jersey.
29. PINSKI J, HALMOS G, SZEPESHAZI K AND SCHALLY AV. (1993). Antagonists of bombesin/gastrin-releasing peptide as adjunct to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Cancer, 72, 3263-3270.
30. POWER RF, MANI SK, CODINA J, CONNEELY OM AND O'MALLEY BW. (1991). Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 254, 1636-1639.
31. ROHR HP, OBERHOLZER M, BARTSCH G AND KELLER M. (1976). Morphometry in experimental pathology: methods, baseline data and applications. Int. Rev. Exp. Pathol., 54, 233-325.
32. SHIKATA H, UTSUMI N, HIRAMATSU M, MINAMI N, NEMOTO N AND SHIKATA T. (1984). Immunohistochemical localization of nerve growth factor and epidermal growth factor in guinea pig prostate gland. Histochemistry, 80, 411-413.
33. TENNISWOOD M. (1986). Role of epithelial stromal interactions in the control of gene expression in the prostate: an hypothesis. Prostate, 9, 375-385.
34. TISCHLER AS AND GREENE LA. (1975). Nerve growth factor-induced process formation by cultured rat phaeochromocytoma cells. Nature, 258, 341-342.
35. ULLRICH A, GARY A, BERMAN C AND DULL TJ. (1983). Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature, 303, 821-825.
36. WILSON POG, BARBER PC, HAMID QA, POWER BF, DHILLON AP, RODE J, DAY INM, THOMPSON RJ AND POLAK JM. (1988). The immunolocalisation of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br. J. Exp. Path., 69, 91-104.
37. YAEGER MJ, KOESTNER A, MARUSHIGE K AND MARUSHIGE Y. (1991). The reverse transforming effects of nerve growth factor on live human neurogenic tumor cell lines: in vitro results. Acta Neuropathol., 83, 72-80.